Drug Trial Radar · NCT05050136
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
333
Actual
Start
Sep 22, 2021
Primary completion
Jan 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Conditions
- Primary Biliary Cholangitis
- PBC
Interventions
VolixibatDrug
Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
PlaceboDrug
Capsules matched to study drug without the active pharmaceutical ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaireTime frame: Baseline to week 28
Locations
130 sites in 15 countries. Site status is shown where the registry gives one.
Southern California Research Center
Coronado, California
Cedars Sinai Medical Center
Los Angeles, California
University of California Los Angeles
Los Angeles, California
UC Davis
Sacramento, California
University of Colorado
Aurora, Colorado
Yale University Digestive Diseases
New Haven, Connecticut
Covenant Metabolic Specialists
Fort Myers, Florida
UF Hepatology Research at CTRB
Gainesville, Florida
UF Health Gastroenterology- Emerson
Jacksonville, Florida
IHS Health
Kissimmee, Florida
Schiff Center for Liver Diseases
Miami, Florida
Advanced Research Institute, Inc
New Port Richey, Florida
Covenant Research and Clinics, LLC
Sarasota, Florida
Tampa General Hospital
Tampa, Florida
Cleveland Clinic Florida
Weston, Florida
Southeast Clinical Research Center
Dalton, Georgia
Northwestern University
Chicago, Illinois
Loyola University Health System - Loyola Outpatient Center
Maywood, Illinois
University of Iowa Hospitals & Clinics
Iowa City, Iowa
Ochsner Clinic Foundation-Baton Rouge
Baton Rouge, Louisiana
LSU Health Science Center Shreveport
Shreveport, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Jackson Liver and GI Specialists
Jackson, Mississippi
CHI Health Clinic (Alegent Creighton Clinic)- Gastroenterology-Bergan
Omaha, Nebraska
Virtua Center for Liver Disease-Camden
Camden, New Jersey
Montefiore Medical Center
The Bronx, New York
Science 37, Inc (Remote-homebased Telemedicine)
Morrisville, North Carolina
Cleveland Clinic - Main Campus
Cleveland, Ohio
Einstein Healthcare Network - Einstein Medical Center
Philadelphia, Pennsylvania
Methodist Le Bonheur Healthcare
Memphis, Tennessee
Galen Medical Group, P.C
Tennessee City, Tennessee
Amel Med LLC
Austin, Texas
The Liver Institute at Methodist Dallas Medical Center
Dallas, Texas
Soma Clinical Trials
Denison, Texas
Baylor College of Medicine
Houston, Texas
Liver Associates of Texas
Houston, Texas
Impact Research
Waco, Texas
University of Utah Health Care
Salt Lake City, Utah
Showing 40 of 130 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.